Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL GENOMIC BIOMARKERS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL XX SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL GENOMIC BIOMARKERS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 OPPUTUNITY MAP ANALYSIS
13 VALUE CHAIN ANALYSIS
14 GLOBAL GENOMICS BIOMARKERS MARKET, BY TYPE
14.1 OVERVIEW
14.2 PREDICTIVE BIOMARKER
14.3 PROGNOSIS BIOMARKER
15 GLOBAL GENOMICS BIOMARKERS MARKET, BY TARGET SITE
15.1 OVERVIEW
15.2 BRCA1
15.3 BRCA2
15.4 EGFR
15.5 ATM
15.6 CHEK1
15.7 CHEK2
15.8 CDK12
15.9 CDK4
15.1 FANCL
15.11 FANCD2
15.12 PALB2
15.13 RAD51B
15.14 RAD51C
15.15 RAD51D
15.16 ALK
15.17 BRAF
15.17.1 V600E
15.17.2 V600K
15.17.3 V600 MUTATION-POSITIVE
15.17.4 OTHERS
15.18 ROS1
15.19 OTHERS
16 GLOBAL GENOMICS BIOMARKERS MARKET, BY VALIDATION
16.1 OVERVIEW
16.2 ANALYTICAL VALIDATION
16.3 CLINICAL VALIDATION
17 GLOBAL GENOMICS BIOMARKERS MARKET, BY TECHNOLOGY
17.1 OVERVIEW
17.2 FUNCTIONAL GENOMICS BIOMARKERS
17.3 EPIGENOMICS BIOMARKERS
17.4 TRANSCRIPTOMICS
17.5 METAGENOMICS BIOMARKERS
17.6 SINGLE-CELL GENOMICS BIOMARKERS
17.7 CRISPR GENOME EDITING TECHNOLOGY
17.8 OTHERS
18 GLOBAL GENOMICS BIOMARKERS MARKET, BY APPLICATION
18.1 OVERVIEW
18.2 CLINICAL
18.3 CANCER
18.3.1 BREAST CANCER
18.3.2 COLORECTAL CANCER
18.3.3 OVARIAN CANCER
18.3.4 PROSTATE CANCER
18.3.5 SOLID CANCER
18.3.6 OTHERS
18.4 INFECTIOUS DISEASES
18.5 CARDIOVASCULAR
18.6 NEUROLOGICAL
18.7 RENAL
18.8 OTHERS
18.9 RESEARCH
18.1 DRUG SCREENING
18.11 TARGET IDENTIFICATION
18.12 BIOMARKER DISCOVERY
18.13 PROTEIN-PROTEIN INTERACTION STUDIES
18.14 PROTEIN THERAPEUTICS
18.15 DISEASE DIAGNOSIS AND MONITORING
18.16 OTHERS
19 GLOBAL GENOMICS BIOMARKERS MARKET, BY END USER
19.1 OVERVIEW
19.2 HOSPITALS & CLINICS
19.3 DIAGNOSTIC CENTERS
19.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
19.5 RESEARCH & ACADEMIC INSTITUTES
19.6 OTHERS
20 GLOBAL GENOMICS BIOMARKERS MARKET, BY DISTRIBTION CHANNEL
20.1 OVERVIEW
20.2 DIRECT TENDERS
20.3 RETAIL SALES
20.4 ONLINE SALES
20.5 OTHERS
21 GLOBAL GENOMIC BIOMARKERS MARKET, SWOT AND DBMR ANALYSIS
22 GLOBAL GENOMIC BIOMARKERS MARKET, COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: GLOBAL
22.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
22.3 COMPANY SHARE ANALYSIS: EUROPE
22.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
22.5 MERGERS & ACQUISITIONS
22.6 NEW PRODUCT DEVELOPMENT & APPROVALS
22.7 EXPANSIONS
22.8 REGULATORY CHANGES
22.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 GLOBAL GENOMIC BIOMARKERS MARKET, BY REGION
GLOBAL GENOMIC BIOMARKERS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1 NORTH AMERICA
23.1.1 U.S.
23.1.2 CANADA
23.1.3 MEXICO
23.2 EUROPE
23.2.1 GERMANY
23.2.2 U.K.
23.2.3 ITALY
23.2.4 FRANCE
23.2.5 SPAIN
23.2.6 RUSSIA
23.2.7 SWITZERLAND
23.2.8 TURKEY
23.2.9 BELGIUM
23.2.10 NETHERLANDS
23.2.11 DENMARK
23.2.12 SWEDEN
23.2.13 POLAND
23.2.14 NORWAY
23.2.15 FINLAND
23.2.16 REST OF EUROPE
23.3 ASIA-PACIFIC
23.3.1 JAPAN
23.3.2 CHINA
23.3.3 SOUTH KOREA
23.3.4 INDIA
23.3.5 SINGAPORE
23.3.6 THAILAND
23.3.7 INDONESIA
23.3.8 MALAYSIA
23.3.9 PHILIPPINES
23.3.10 AUSTRALIA
23.3.11 NEW ZEALAND
23.3.12 VIETNAM
23.3.13 TAIWAN
23.3.14 REST OF ASIA-PACIFIC
23.4 SOUTH AMERICA
23.4.1 BRAZIL
23.4.2 ARGENTINA
23.4.3 REST OF SOUTH AMERICA
23.5 MIDDLE EAST AND AFRICA
23.5.1 SOUTH AFRICA
23.5.2 EGYPT
23.5.3 BAHRAIN
23.5.4 UNITED ARAB EMIRATES
23.5.5 KUWAIT
23.5.6 OMAN
23.5.7 QATAR
23.5.8 SAUDI ARABIA
23.5.9 REST OF MEA
23.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24 GLOBAL GENOMIC BIOMARKERS MARKET, COMPANY PROFILE
24.1 MYRIAD GENETICS
24.1.1 COMPANY OVERVIEW
24.1.2 REVENUE ANALYSIS
24.1.3 GEOGRAPHIC PRESENCE
24.1.4 PRODUCT PORTFOLIO
24.1.5 RECENT DEVELOPMENTS
24.2 ALMAC GROUP
24.2.1 COMPANY OVERVIEW
24.2.2 REVENUE ANALYSIS
24.2.3 GEOGRAPHIC PRESENCE
24.2.4 PRODUCT PORTFOLIO
24.2.5 RECENT DEVELOPMENTS
24.3 QAIGEN
24.3.1 COMPANY OVERVIEW
24.3.2 REVENUE ANALYSIS
24.3.3 GEOGRAPHIC PRESENCE
24.3.4 PRODUCT PORTFOLIO
24.3.5 RECENT DEVELOPMENTS
24.4 MEDGENOME
24.4.1 COMPANY OVERVIEW
24.4.2 REVENUE ANALYSIS
24.4.3 GEOGRAPHIC PRESENCE
24.4.4 PRODUCT PORTFOLIO
24.4.5 RECENT DEVELOPMENTS
24.5 SEMA4
24.5.1 COMPANY OVERVIEW
24.5.2 REVENUE ANALYSIS
24.5.3 GEOGRAPHIC PRESENCE
24.5.4 PRODUCT PORTFOLIO
24.5.5 RECENT DEVELOPMENTS
24.6 F. HOFFMAN LA ROCHE LTD
24.6.1 COMPANY OVERVIEW
24.6.2 REVENUE ANALYSIS
24.6.3 GEOGRAPHIC PRESENCE
24.6.4 PRODUCT PORTFOLIO
24.6.5 RECENT DEVELOPMENTS
24.7 THERMOFISHER SCIENTIFIC INC.
24.7.1 COMPANY OVERVIEW
24.7.2 REVENUE ANALYSIS
24.7.3 GEOGRAPHIC PRESENCE
24.7.4 PRODUCT PORTFOLIO
24.7.5 RECENT DEVELOPMENTS
24.8 ILLUMINA INC.
24.8.1 COMPANY OVERVIEW
24.8.2 REVENUE ANALYSIS
24.8.3 GEOGRAPHIC PRESENCE
24.8.4 PRODUCT PORTFOLIO
24.8.5 RECENT DEVELOPMENTS
24.9 DISCOVERY LIFE SCIENCES
24.9.1 COMPANY OVERVIEW
24.9.2 REVENUE ANALYSIS
24.9.3 GEOGRAPHIC PRESENCE
24.9.4 PRODUCT PORTFOLIO
24.9.5 RECENT DEVELOPMENTS
24.1 CREATIVE DIAGNOSTICS
24.10.1 COMPANY OVERVIEW
24.10.2 REVENUE ANALYSIS
24.10.3 GEOGRAPHIC PRESENCE
24.10.4 PRODUCT PORTFOLIO
24.10.5 RECENT DEVELOPMENTS
24.11 QUNATERIX
24.11.1 COMPANY OVERVIEW
24.11.2 REVENUE ANALYSIS
24.11.3 GEOGRAPHIC PRESENCE
24.11.4 PRODUCT PORTFOLIO
24.11.5 RECENT DEVELOPMENTS
24.12 CD GENOMICS
24.12.1 COMPANY OVERVIEW
24.12.2 REVENUE ANALYSIS
24.12.3 GEOGRAPHIC PRESENCE
24.12.4 PRODUCT PORTFOLIO
24.12.5 RECENT DEVELOPMENTS
24.13 BGI
24.13.1 COMPANY OVERVIEW
24.13.2 REVENUE ANALYSIS
24.13.3 GEOGRAPHIC PRESENCE
24.13.4 PRODUCT PORTFOLIO
24.13.5 RECENT DEVELOPMENTS
24.14 TAKARA BIO INC
24.14.1 COMPANY OVERVIEW
24.14.2 REVENUE ANALYSIS
24.14.3 GEOGRAPHIC PRESENCE
24.14.4 PRODUCT PORTFOLIO
24.14.5 RECENT DEVELOPMENTS
24.15 MERCK KGAA
24.15.1 COMPANY OVERVIEW
24.15.2 REVENUE ANALYSIS
24.15.3 GEOGRAPHIC PRESENCE
24.15.4 PRODUCT PORTFOLIO
24.15.5 RECENT DEVELOPMENTS
24.16 GENWIZ
24.16.1 COMPANY OVERVIEW
24.16.2 REVENUE ANALYSIS
24.16.3 GEOGRAPHIC PRESENCE
24.16.4 PRODUCT PORTFOLIO
24.16.5 RECENT DEVELOPMENTS
25 RELATED REPORTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
